Search hospitals > Hawaii > Honolulu
University of Hawaii Cancer Center
Claim this profileHonolulu, Hawaii 96813
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Lung Cancer
Conducts research for Breast cancer
Conducts research for Ovarian Cancer
313 reported clinical trials
12 medical researchers
Summary
University of Hawaii Cancer Center is a medical facility located in Honolulu, Hawaii. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Breast cancer, Ovarian Cancer and other specialties. University of Hawaii Cancer Center is involved with conducting 313 clinical trials across 468 conditions. There are 12 research doctors associated with this hospital, such as Jeffrey L. Berenberg, Jared D. Acoba, Jami A. Fukui, and Michael Carney, MD.Area of expertise
1Breast Cancer
Global LeaderER positive
HER2 negative
Stage IV
2Cancer
Global LeaderStage IV
Stage I
Stage II
Top PIs
Jeffrey L. BerenbergStraub Clinic and Hospital2 years of reported clinical research
Expert in Lung Cancer
Studies Non-Small Cell Lung Cancer
29 reported clinical trials
77 drugs studied
Jared D. AcobaQueen's Medical Center2 years of reported clinical research
Studies Colon Cancer
Studies Pancreatic Cancer
18 reported clinical trials
38 drugs studied
Jami A. FukuiKapiolani Medical Center for Women and Children6 years of reported clinical research
Studies Breast Cancer
Studies Breast cancer
14 reported clinical trials
35 drugs studied
Michael Carney, MDKapiolani Medical Center for Women and Children5 years of reported clinical research
Expert in Ovarian Cancer
Studies Fallopian Tube Cancer
14 reported clinical trials
29 drugs studied
Clinical Trials running at University of Hawaii Cancer Center
Lung Cancer
Ovarian Cancer
Breast Cancer
Cancer
Breast cancer
Prostate Cancer
Pancreatic Cancer
Esophageal cancer
Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Radiation Therapy
for Brain Metastasis
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.
Recruiting2 awards Phase 312 criteria
High-Dose Radiation + Chemotherapy and Immunotherapy
for Non-Small Cell Lung Cancer
This trial tests whether adding a precise form of radiation therapy to the usual treatment improves outcomes for patients with advanced lung cancer that can't be operated on. The goal is to see if this combination helps patients live longer and prevents cancer from worsening. This form of radiation therapy has shown promise in improving survival rates in patients with various stages of lung cancer.
Recruiting2 awards Phase 314 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at University of Hawaii Cancer Center?
University of Hawaii Cancer Center is a medical facility located in Honolulu, Hawaii. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Breast cancer, Ovarian Cancer and other specialties. University of Hawaii Cancer Center is involved with conducting 313 clinical trials across 468 conditions. There are 12 research doctors associated with this hospital, such as Jeffrey L. Berenberg, Jared D. Acoba, Jami A. Fukui, and Michael Carney, MD.
Where is University of Hawaii Cancer Center located?
The University of Hawaii Cancer Center is located at 701 Ilalo Street, Suite 600, Honolulu, HI 96813.
Who should I call to ask about financial aid or insurance network?
**University of Hawaii Cancer Center Contact Information:**
- General Inquiries: (808) 586-3010, Email: [email protected]
- Patient-Related Matters: Phone: (808) 586-5854, Fax: (808) 586-5857
**Hawaii Society of Clinical Oncology (HSCO):**
- Offers financial advocacy and patient assistance resources.
**UHA Health Insurance:**
- Customer Service: (808) 532-4000, Toll-Free: (800) 458-4600
What insurance does University of Hawaii Cancer Center accept?
The University of Hawaii Cancer Center accepts the UH Student Plan (HMSA), providing comprehensive coverage for students enrolled in the University of Hawaii system who meet the credit requirement. This plan is widely accepted across Hawaii and offers medical, prescription drug, laboratory, radiology, mental health, family planning, medical evacuation, and overseas travel benefits. Additional benefits such as Dental, Repatriation, Life Insurance, and Accidental Death & Dismemberment can be purchased separately.
What awards or recognition has University of Hawaii Cancer Center received?
The University of Hawaii Cancer Center, designated by the National Cancer Institute (NCI) since 1996, specializes in cutting-edge cancer research, focusing on the diverse populations in Hawaii and the Pacific. It has received continuous NCI funding for the Multiethnic Cohort (MEC) Study, tracking over 215,000 residents of Hawaii and Los Angeles for cancer and chronic disease development. This recognition enables the center to secure an average of $40 million annually in grants.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.